Mayne Pharma Secures $14.4M Legal Costs from Cosette After Court Ruling
Mayne Pharma has received $14.4 million from Cosette Pharmaceuticals covering legal costs and interest following a Supreme Court ruling in its favour. The legal battle continues with Cosette’s appeal decision pending.
- Mayne Pharma awarded $14.4 million for legal costs
- Payment ordered by Supreme Court of New South Wales
- Court dismissed all claims by Cosette in October 2025
- Cosette has filed an appeal with decision reserved
- Legal dispute stems from terminated Scheme Implementation Deed
Substantial Legal Cost Recovery Boosts Mayne Pharma
Mayne Pharma (ASX:MYX) has received a significant $14.4 million payment from Cosette Pharmaceuticals, ordered by the Supreme Court of New South Wales. This sum covers Mayne Pharma’s legal costs, costs related to their application for costs, plus interest, marking a notable financial win in the ongoing legal dispute between the two companies.
Background of the Legal Dispute
The dispute traces back to June 2025 when Mayne Pharma initiated proceedings after Cosette purportedly terminated a Scheme Implementation Deed signed earlier that year. The Supreme Court ruled in October 2025 in favour of Mayne Pharma, dismissing all claims brought by Cosette and imposing an adverse costs order requiring Cosette to pay Mayne Pharma’s legal expenses.
This legal victory was earlier reported when the court awarded Mayne Pharma $13.27 million in legal costs, a figure that has now grown to $14.4 million with accrued interest and additional costs. The payment reflects the court’s firm stance on the contractual obligations and the costs of litigation incurred by Mayne Pharma in defending its position.
Appeal Keeps Legal Uncertainty Alive
Despite the payment, the legal battle is not over. Cosette lodged an appeal against the October 2025 judgment, with the hearing conducted on 2 and 3 June 2026. The Court of Appeal has reserved its decision, leaving the final outcome uncertain. This pending appeal means the financial and legal implications for Mayne Pharma could still evolve, depending on the appellate court’s ruling.
Implications for Mayne Pharma’s Strategic Focus
While the legal proceedings have demanded significant attention, Mayne Pharma continues to focus on its core pharmaceutical business, including its dermatology and women’s health portfolios. The recent legal cost recovery provides a financial boost that may support ongoing investments and operational priorities. However, the shadow of the appeal means investors should watch closely for any shifts in the legal landscape that could affect Mayne Pharma’s position.
Bottom Line?
Mayne Pharma’s $14.4 million legal cost recovery is a win, but the pending appeal keeps the dispute’s final impact uncertain.
Questions in the middle?
- How will the Court of Appeal’s decision affect Mayne Pharma’s legal and financial position?
- Could the legal costs recovered influence Mayne Pharma’s investment in product development?
- What are the broader implications for acquisition deals in the pharmaceutical sector following this dispute?
